Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...
Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...
Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...
EST Halozyme (HALO) announces new $250M accelerated share repurchase plan Stay Ahead of the Market:Discover outperforming stocks and ...
FY25 consensus $4.69. Raises FY25 revenue view to $1.15B-$1.225B from $1.095B-$1.17B, consensus $1.16B.Stay Ahead of the Market:Discover ...
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of TC Biopharm shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares ...
Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of ...
Zacks.com on MSN3h
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets GoalShares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and ...
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...
(Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback